NU6102
| Code | Size | Price |
|---|
| TAR-T28218-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28218-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
NU6102 is a potent inhibitor of Cdk1, Cdk2 and Cdk4 (Cdk1, Ki = 9 nM, IC50 = 9.5 nM; Cdk2, Ki = 6 nM, IC50 = 5.4 nM; Cdk4, IC50 = 1.6 μM).
CAS:
444722-95-6
Formula:
C18H22N6O3S
Molecular Weight:
402.47
Purity:
0.98
SMILES:
NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1
References
1. Beale G, Haagensen EJ, Thomas HD, Wang LZ, Revill CH, Payne SL, Golding BT, Hardcastle IR, Newell DR, Griffin RJ, Cano C. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. Br J Cancer. 2016 Sep 6;115(6):682-90. doi: 10.1038/bjc.2016.238. PubMed PMID: 27529512; PubMed Central PMCID: PMC5023777.
2. Trevi?o LS, Bolt MJ, Grimm SL, Edwards DP, Mancini MA, Weigel NL. Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK. Mol Endocrinol. 2016 Feb;30(2):158-72. doi: 10.1210/me.2015-1144. PubMed PMID: 26652902; PubMed Central PMCID: PMC4792227.
3. Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble ME, Wedge SR, Endicott JA, Griffin RJ. Identification and Characterization of an Irreversible Inhibitor of CDK2. Chem Biol. 2015 Sep 17;22(9):1159-64. doi: 10.1016/j.chembiol.2015.07.018. PubMed PMID: 26320860; PubMed Central PMCID: PMC4579270.
4. Moore NL, Edwards DP, Weigel NL. Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cells. J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:471-82. doi: 10.1016/j.jsbmb.2014.09.009. PubMed PMID: 25220500; PubMed Central PMCID: PMC4201666.